C-550-01 A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with AGEN2034 in Subjects with Metastatic or Locally Advanced Solid Tumours, and Expansion into Select Solid Tumours
Phase of Trial: Phase I/II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs AGEN 1884 (Primary) ; AGEN 2034 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 22 Jan 2018 According to an Agenus media release, enrollment into the first cohort of the trial has been completed.
- 15 Mar 2017 New trial record
- 09 Mar 2017 According to an Agenus Inc. media release, this trial is expected to initiate in the second half of 2017.